1690318-25-2

1690318-25-2 structure

Name: Crizanlizumab
Chemical Name: Crizanlizumab
CAS Number: 1690318-25-2
Molecular Formula:
Molecular Weight:
Catalog: Research Areas Cardiovascular Disease
Create Date: 2023-02-25 03:17:21
Modify Date: 2024-04-06 11:07:08
Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease[1][2][3].

Name	Crizanlizumab

Description	Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease[1][2][3].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> Others >> Others
Target	P-selectin[2]
References	[1]. Hannah A. Blair, et al. Crizanlizumab: First Approval. Drugs. 80, 79-84 (2020). [2]. Ataga KI, et al. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. N Engl J Med. 2017 Feb 2;376(5):429-439. [3]. Ravirajsinh Jadeja, et al. Therapeutic potential of Crizanlizumab (anti-P-selectin) in improving sickle cell retinopathy in mice. Investigative Ophthalmology & Visual Science June 2023, Vol.64, 4747.

No Any Chemical & Physical Properties